Press Releases Sandoz Group AG

Equities

SDZ

CH1243598427

Market Closed - Swiss Exchange Other stock markets 09:00:12 24/05/2024 pm IST			5-day change	1st Jan Change
32.02 ^CHF	-0.93%		+0.09%	+18.33%

22/05	Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	CF
22/05	Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe	23/05	AQ
European Commission grants first-of-a-kind biosimilar approval	23/05	AQ
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe	22/05	GL
Sandoz reports first quarter 2024 sales	07/05	GL
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	30/04	GL
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars	30/04	GL
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering	22/04	GL
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines	21/03	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	13/03	GL
Sandoz reports fourth quarter 2023 sales and full-year 2023 results	13/03	AQ
Sandoz receives FDA approval for first and only denosumab biosimilars	05/03	GL
Sandoz announces nominations to the Board of Directors and leadership change	05/03	GL
Sandoz announces nominations to the Board of Directors and leadership change	05/03	AQ
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	04/03	GL
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	04/03	AQ
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs	29/02	GL
Sandoz announces changes in the Board of Directors	01/02	GL
Sandoz announces changes in the Board of Directors	01/02	AQ
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany	31/01	GL
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany	31/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SANDOZ : Sandoz’s improvements are worth betting on

May 08, 2024 at 05:38 pm IST